SPIOLTO

This brand name is authorized in Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom

Active ingredients

The drug SPIOLTO contains a combination of these active pharmaceutical ingredients (APIs):

1 Tiotropium
UNII L64SXO195N - TIOTROPIUM BROMIDE MONOHYDRATE

Tiotropium is a long-acting, specific, muscarinic receptor antagonist, in clinical medicine often called an anticholinergic. By binding to the muscarinic receptors in the bronchial smooth musculature, tiotropium inhibits the cholinergic (bronchoconstrictive) effects of acetylcholine, released from parasympathetic nerve endings.

Read about Tiotropium
2 Olodaterol
UNII 65R445W3V9 - OLODATEROL HYDROCHLORIDE

Olodaterol has a high affinity and high selectivity to the human beta2-adrenoceptor. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after topical administration by inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3',5' adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells.

Read about Olodaterol

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
SPIOLTO RESPIMAT Inhalation solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R03AL06 Olodaterol and tiotropium bromide R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AL Adrenergics in combination with anticholinergics
Discover more medicines within R03AL06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10557P
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 504520010021207
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 1559-MEE-1215
Country: EE Ravimiamet Identifier(s): 1648481, 1648492, 1648504, 1648515
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 79967
Country: FR Base de données publique des médicaments Identifier(s): 63620349
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 299714, 376781
Country: HK Department of Health Drug Office Identifier(s): 64356
Country: IE Health Products Regulatory Authority Identifier(s): 46802, 46803
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7839
Country: JP 医薬品医療機器総合機構 Identifier(s): 2259807G1026, 2259807G2022
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1086460, 1086461, 1086462, 1086463
Country: MT Medicines Authority Identifier(s): MA211/00701
Country: NL Z-Index G-Standaard, PRK Identifier(s): 127086
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 17124
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100346050
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W61818005, W61818006, W61818007, W61818008
Country: SG Health Sciences Authority Identifier(s): 14923P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 11533081

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.